First Trust Advisors LP lowered its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 55.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 16,159 shares of the life sciences company’s stock after selling 20,279 shares during the quarter. First Trust Advisors LP’s holdings in Integra LifeSciences Holdings Corporation were worth $881,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of IART. LS Investment Advisors LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 90.7% during the 1st quarter. LS Investment Advisors LLC now owns 2,412 shares of the life sciences company’s stock valued at $102,000 after acquiring an additional 1,147 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Integra LifeSciences Holdings Corporation by 223.6% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,534 shares of the life sciences company’s stock valued at $107,000 after acquiring an additional 1,751 shares during the last quarter. Turner Investments LLC acquired a new position in shares of Integra LifeSciences Holdings Corporation during the 1st quarter valued at about $126,000. Meadow Creek Investment Management LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 121.2% during the 1st quarter. Meadow Creek Investment Management LLC now owns 4,088 shares of the life sciences company’s stock valued at $172,000 after acquiring an additional 2,240 shares during the last quarter. Finally, SG Americas Securities LLC increased its stake in shares of Integra LifeSciences Holdings Corporation by 56.9% during the 1st quarter. SG Americas Securities LLC now owns 4,294 shares of the life sciences company’s stock valued at $181,000 after acquiring an additional 1,557 shares during the last quarter. 84.90% of the stock is owned by institutional investors.

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) opened at 48.31 on Friday. Integra LifeSciences Holdings Corporation has a one year low of $37.71 and a one year high of $56.42. The stock has a market cap of $3.77 billion, a PE ratio of 58.91 and a beta of 0.73. The stock’s 50 day moving average price is $50.51 and its 200-day moving average price is $48.58.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The company had revenue of $282.16 million during the quarter, compared to the consensus estimate of $283.58 million. During the same period last year, the business earned $0.40 EPS. The business’s quarterly revenue was up 13.2% on a year-over-year basis. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

In other news, Director Barbara B. Hill purchased 5,050 shares of the business’s stock in a transaction dated Tuesday, August 1st. The stock was bought at an average cost of $49.33 per share, with a total value of $249,116.50. Following the purchase, the director now directly owns 44,772 shares of the company’s stock, valued at $2,208,602.76. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Donald E. Morel, Jr. purchased 10,000 shares of the business’s stock in a transaction dated Friday, August 4th. The shares were purchased at an average cost of $49.25 per share, with a total value of $492,500.00. Following the completion of the purchase, the director now directly owns 29,612 shares in the company, valued at $1,458,391. The disclosure for this purchase can be found here. Insiders have bought a total of 17,550 shares of company stock valued at $864,842 over the last ninety days. Company insiders own 21.50% of the company’s stock.

IART has been the subject of a number of research analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $65.00 price objective on shares of Integra LifeSciences Holdings Corporation in a research note on Monday, July 10th. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corporation from a “sell” rating to a “hold” rating in a research note on Thursday, July 27th. Raymond James Financial, Inc. upped their price objective on shares of Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, July 27th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corporation in a research note on Wednesday, July 26th. Finally, BidaskClub downgraded shares of Integra LifeSciences Holdings Corporation from a “buy” rating to a “hold” rating in a research note on Monday, July 24th. Five analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Integra LifeSciences Holdings Corporation has a consensus rating of “Buy” and a consensus target price of $53.54.

COPYRIGHT VIOLATION NOTICE: “Integra LifeSciences Holdings Corporation (IART) Shares Sold by First Trust Advisors LP” was first published by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-shares-sold-by-first-trust-advisors-lp/1579293.html.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.